Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 2:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2761–2784 of 6,929 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Stimulation Clear all

Conditions: Neuralgia, Neuropathic Pain, Painful Diabetic Neuropathy
Interventions: Axon Therapy and CMM, Sham and CMM; Device
Lead sponsor: NeuraLace Medical, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 7
States / cities: Sebastian, Florida • St. Petersburg, Florida • Vero Beach, Florida + 4 more

Conditions: Suicide, Depression, Anxiety, Insomnia, Agitation
Interventions: Alpha-Stim®., Montgomery-Åsberg Depression Rating Scale, Hamilton Anxiety Rating Scale, The Pittsburgh Sleep Quality Index and agitated behavior Scale; Device · Behavioral
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Neuropathic Pain, Amputation
Interventions: SPRINT Peripheral Nerve Stimulation (PNS) System; Device
Lead sponsor: SPR Therapeutics, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 14
States / cities: Phoenix, Arizona • La Jolla, California • Orlando, Florida + 11 more

Conditions: Depression - Major Depressive Disorder, Treatment-resistant Depression (TRD), rTMS, Ketamine, fMRI
Interventions: TMS, Ketamine; Device · Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: New York, New York

Conditions: Early Stage Breast Cancer
Interventions: Paclitaxel, Neulasta; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 4
States / cities: Boston, Massachusetts • Milford, Massachusetts • Weymouth, Massachusetts + 1 more

Conditions: Hereditary Pulmonary Alveolar Proteinosis
Interventions: Leukine; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 8 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Cincinnati, Ohio • Richmond, Virginia

Conditions: Parkinson Disease
Interventions: Frequency change to 60 Hz, Frequency change to 130 Hz; Procedure
Lead sponsor: Vanderbilt University; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: High Grade Glioma, CNS Tumor
Interventions: Entrectinib, Cyclophosphamide, Etoposide, Carboplatin, G-CSF, Pegfilgrastim, Surgery; Drug · Biological · Procedure
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 3 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Primary Care
Interventions: Relational Agent ( RA) Alex; Behavioral
Lead sponsor: Anita Y. Kinney, PhD, RN; Other
Eligibility: 18 Years to 70 Years
Enrollment: 210 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Major Depressive Disorder
Interventions: SAINT® Neuromodulation System (NMS); Device
Lead sponsor: Magnus Medical; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 7
States / cities: Costa Mesa, California • Los Angeles, California • Sunnyvale, California + 3 more

Conditions: Healthy Volunteers
Interventions: Temporal Interference (TI) Electrical Stimulation - NAcc TI Active, Temporal Interference (TI) Electrical Stimulation - NAcc TI Sham, Temporal Interference (TI) Electrical Stimulation - NAcc No-TI Active, Temporal Interference (TI) Electrical Stimulation - NAcc No-TI Sham; Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Bloomington, Indiana

Conditions: Posterior Fossa Ependymoma (PFEPN)
Interventions: Trastuzumab after SubQ GM-CSF, Trastuzumab in combination with SubQ GM-CSF; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 12 Months to 21 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Cerebral Palsy
Interventions: Stochastic resonance (SR) wraps; Device
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 3 Years to 18 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Chronic Shoulder Pain
Interventions: SPRINT PNS; Device
Lead sponsor: Gramercy Pain Center; Other
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Holmdel, New Jersey

Conditions: Neuroblastoma
Interventions: Thiotepa, Cyclophosphamide, Melphalan, Etoposide, Carboplatin, Autologous Stem Cell Infusion, Granulocyte colony stimulating factor; Drug · Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 30 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Cervical Spinal Cord Injury
Interventions: FTP Alone, FTP+Con-FES, FTP+WPHF-FES; Behavioral
Lead sponsor: Craig Hospital; Other
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Englewood, Colorado

Conditions: Urinary Bladder, Overactive
Interventions: MagPro R30; Device
Lead sponsor: EMKinetics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Chronic Pain, Opioid Use
Interventions: Empower Neuromodulation System Transcutaneous Electrical Nerve Stimulation; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Obsessive-Compulsive Disorder
Interventions: Virtual Reality; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Metastatic Cancer, Epithelial Tumor
Interventions: NG-641; Biological
Lead sponsor: Akamis Bio; Industry
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 6
States / cities: Los Angeles, California • Santa Barbara, California • Celebration, Florida + 3 more

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Sargramostim, Ganciclovir; Drug
Lead sponsor: Schering-Plough; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 14
States / cities: Los Angeles, California • San Francisco, California • Sherman Oaks, California + 7 more

Conditions: Obstructive Sleep Apnea
Interventions: Inspire® UAS System; Device
Lead sponsor: Inspire Medical Systems, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • Miami, Florida + 9 more

Conditions: Transitional Cell Carcinoma
Interventions: TICE®-strain BCG, NY-ESO-1 protein, sargramostim; Biological
Lead sponsor: Ludwig Institute for Cancer Research; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Stroke
Interventions: kTMP; Device
Lead sponsor: Magnetic Tides; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Berkeley, California

Search by objective public record fields.

Axon Therapy and Conventional Medical Management for Painful Diabetic Neuropathy Compared to Sham and Conventional Medical Management

Cranial Electric Stimulation to Modify Suicide Risk Factors in Psychiatric Inpatients.

The SNAP Trial: SPRINT® Peripheral Nerve Stimulation for the Treatment of Neuropathic Post-Amputation Pain

Biomarker-Guided Antidepressant Selection

Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer

Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP)

Deep Brain Stimulation (DBS) Frequency Effects on Gait in Parkinson's Disease(PD)

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

Project CARE: CAncer Risk Evaluation

Open Label Optimization Study

Temporal Interference Methods for Non-invasive Deep Brain Stimulation, Study 1.1

Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma

Investigating the Effect of Stochastic Resonance Vibration on Gait and Balance and Upper Extremity Function in Children With Cerebral Palsy

Treatment of Shoulder Osteoarthritis

Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

Improving Upper Extremity Function and Trunk Stability After Cervical Spinal Cord Injury (SCI)

Pulsed Electromagnetic Stimulation for Treatment of Overactive Bladder

Empower Opioid Misuse & Chronic Pain

Using Virtual Reality Before Transcranial Magnetic Stimulation for the Treatment of OCD

First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector

Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis

Inspire® Post-Approval Study / Protocol Number 2014-001

Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas

Pilot Study: A Novel Method of Non-Invasive Brain Stimulation (kTMP) to Enhance Motor Function in Chronic Stroke Patients